SUBSCRIPTION AGREEMENTSubscription Agreement • July 11th, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Delaware
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING.
PUBLIC HEALTH SERVICE SECOND AMENDMENT TO L-216-2000/0Second Amendment • July 11th, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories
This is the second amendment (“Second Amendment”) of the agreement by and between the National Institutes of Health (“NIH”) or the Food and Drug Administration (“FDA”), hereinafter singly or collectively referred to as agencies of the United States Public Health Service (“PHS”) within the Department of Health and Human Services (“HHS”), and 20/20 GeneSystems, Inc. having an effective date of November 9, 2000, and having NIH Reference Number L-216-2000/0, as amended by the first amendment to the agreement, having an effective date of April 14, 2005, and having NIH reference Number L-216-2000/1 (“First Amendment”) (hereinafter collectively referred to as the “Agreement”). This Second Amendment, having NIH Reference Number L-216-2000/2, is made between the PHS through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and 20/20 GeneSystems, Inc., having an office at 9430 Key West Ave. Rockville, MD 2085
LICENSE AMENDMENT20/20 GeneSystems, Inc. • July 11th, 2018 • Services-testing laboratories
WHEREAS, the National Institutes of Health (“NIH”) on behalf of the Public Health Service (“PHS”), Department of Health and Human Services (“DHHS”) and 20/20 GeneSystems, Inc. (“Licensee”) entered into a license agreement (PHS Ref. L-216-2000/0; “Agreement”) effective November 9, 2000, relating to U. S. Patent Application S/N 60/145,613, filed July 26, 1999, entitled “Methods for Production of Layered Expression Scans for Tissue and Cell Samples” (and PCT filed on July 26, 2000, PCT/US00/20354); and
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT--EXCLUSIVE COVER PAGEPatent License Agreement • July 11th, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • District of Columbia
US Patent Application Serial No. 60/145,613 entitled “Method for Production of Layered Expression Scans for Tissue and Cell Samples”, filed 07/26/99. PCT filed 07/26/2000 (PCT/US00/20354)
Project Accelerator Program AWARD AND ROYALTY AGREEMENTAward and Royalty Agreement • July 11th, 2018 • 20/20 GeneSystems, Inc. • Services-testing laboratories • Maryland
THIS AWARD AND ROYALTY AGREEMENT is made this 19th day of July 2002, by and between MdBio, Inc., a Maryland non-stock, not-for-profit corporation ("MdBio") and 20/20 GeneSystems, Inc., a Delaware corporation with its headquarters located at Rockville, Maryland ("20/20").
